 |
|
Statin therapy may lower mortality in heart failure patients
July 25, 2005WINSTON-SALEM, N.C. - Cholesterol-lowering statin therapy may improve survival in patients with diastolic heart failure (DHF) according to a paper published in Circulation: Journal of the American Heart Association by cardiologists at Wake Forest University Baptist Medical Center.
Currently, there are no treatments shown to improve survival in these patients, who make up about 40 percent of all heart failure cases. Systolic heart failure patients have hearts that don't pump out enough blood. In DHF, the heart does not fully relax and therefore does not fill properly with blood. The mortality rate is 5 to 8 percent per year.
William C. Little, M.D., head of the cardiology section at Wake Forest Baptist, and his research team found a dramatic difference in the longevity of 137 diastolic heart failure patients followed over a three-year period. The patients were being treated with ACE inhibitors, beta-blockers, calcium blockers or statins - all drugs that are commonly used to treat hypertension or heart-related conditions.
"Some patients in the group had been diagnosed with high cholesterol and placed on statin therapy by their doctors. Others in the group whose cholesterol levels were not as high in general, were not placed on statins," said Little. "But when we followed the patients we found that those who had received statins did dramatically better."
Little and his research team found that during the study period, heart failure patients on statin therapy had a risk of death that was 22 percent lower than the patients receiving the other drugs. Even after adjusting for other factors that could have affected the results, such as hypertension or cardiovascular disease, the heart failure patients on statins still fared better.
Little writes that the improved survival rates in the study might be due to the known beneficial effects of statins in patients with coronary artery disease. Whether diagnosed or not, coronary artery disease is quite common in the elderly population. Too, because diabetes and impaired kidney function are also common in patients with diastolic failure, statins may improve the outcome of these conditions, possibly explaining some of the benefits observed by his team with statins in diastolic heart failure.
"Because the patients were not randomized to which therapy they received, this is not a definitive study," said Little. "However, it certainly suggests that it's worth looking into using statins to treat patients with diastolic heart failure."
According to previous reports in Circulation as well as the New England Journal of Medicine, diastolic heart failure is a significant healthcare problem. Once hospitalized, patients with diastolic heart failure have a 50 percent chance of rehospitalization within six months. It's estimated that the cost of treating patients for diastolic heart failure exceeds $3.5 billion a year.
Co-authors of the report include Hidekatsu Fukuta, M.D. international research fellow, Nagoya Medical School, Japan, David C. Sane, M.D., associate professor of medicine, Wake Forest Baptist, and Steffen Brucks, M.D., international research fellow, University of Magdengurg, Germany.
Wake Forest University Baptist Medical Center
"Some patients in the group had been diagnosed with high cholesterol and placed on statin therapy by their doctors. Others in the group whose cholesterol levels were not as high in general, were not placed on statins," said Little. "But when we followed the patients we found that those who had received statins did dramatically better."
Little and his research team found that during the study period, heart failure patients on statin therapy had a risk of death that was 22 percent lower than the patients receiving the other drugs. Even after adjusting for other factors that could have affected the results, such as hypertension or cardiovascular disease, the heart failure patients on statins still fared better.
Little writes that the improved survival rates in the study might be due to the known beneficial effects of statins in patients with coronary artery disease. Whether diagnosed or not, coronary artery disease is quite common in the elderly population. Too, because diabetes and impaired kidney function are also common in patients with diastolic failure, statins may improve the outcome of these conditions, possibly explaining some of the benefits observed by his team with statins in diastolic heart failure.
"Because the patients were not randomized to which therapy they received, this is not a definitive study," said Little. "However, it certainly suggests that it's worth looking into using statins to treat patients with diastolic heart failure."
According to previous reports in Circulation as well as the New England Journal of Medicine, diastolic heart failure is a significant healthcare problem. Once hospitalized, patients with diastolic heart failure have a 50 percent chance of rehospitalization within six months. It's estimated that the cost of treating patients for diastolic heart failure exceeds $3.5 billion a year.
Co-authors of the report include Hidekatsu Fukuta, M.D. international research fellow, Nagoya Medical School, Japan, David C. Sane, M.D., associate professor of medicine, Wake Forest Baptist, and Steffen Brucks, M.D., international research fellow, University of Magdengurg, Germany.
Wake Forest University Baptist Medical Center
Statins Current Events and Statins News RSSEarly end to key study on benefits of niacin, a B vitamin, in keeping arteries open was premature
Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing.
Researchers mobilizing global resources to test new treatments for severe H1N1 infection
An important, ground-breaking initiative is unfolding in the global critical care community in response to the H1N1 pandemic.
Widely used cholesterol-lowering drug may prevent progression
Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease.
Statins show dramatic drug and cell dependent effects in the brain
Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia.
Cholesterol-lowering medicines may be effective against cancer
Statins lower cholesterol by blocking certain enzymes involved in our metabolism.
Adding ezetimibe to atorvastatin improves lipid control
Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone.
Use of statins favors the wealthy, creating new social disparities in cholesterol
Since the introduction of statins to treat high cholesterol, the decline in lipid levels experienced by the wealthy has been double that experienced by the poor.
Women with Atrial Fibrillation Are at Significantly Higher Risk of Stroke and Death Compared to Men and Receive Less Attention
Even though the incidence of atrial fibrillation is higher in men than women, a review of past studies and medical literature completed by cardiac experts at Rush University Medical Center shows that women are more likely than men to experience symptomatic attacks, a higher frequency of recurrences, and significantly higher heart rates during atrial fibrillation, which increases the risk of stroke.
Pre-hospital organization: The first links in the chain of survival for heart attack patients
Mortality rate following a heart attack has fallen by more than 50% in Europe over the past 25 years. However, because only minor advances in the medical treatment of AMI are expected over the next decade, it is through organisational changes in the pre-hospital phase that mortality rate will continue this decline to below 5%.
Fatostatin' is a turnoff for fat genes
A small molecule earlier found to have both anti-fat and anti-cancer abilities works as a literal turnoff for fat-making genes, according to a new report in the August 28th issue of the journal Chemistry and Biology, a Cell Press journal.
More Statins Current Events and Statins News Articles
 |
The Statin Damage Crisis by Duane Graveline (Author), Malcolm Kendrick (Introduction) The purpose in the choice of the title The Statin Damage Crisis is to draw attention to the thousands of statin damaged people who have written to Dr Graveline about their disabling neuropathies, myopathies and a variety of neurodegenerative conditions such as ALS and Parkinsonism associated with statin use. Although much of the book's content will be familiar to readers of Statin Drugs Side Effects, ( this was originally planned as a new edition ) the Statin Damage Crisis adds much new material that Dr Graveline has learned of in the past two years. Dr Graveline states: "Early on my NASA doctors told me my amnesia response to statins was nothing but a coincidence but I persevered to write my first book, Lipitor, Thief of Memory." "Then I learned of statin damage to nerves and... |
 |
Statin Drugs Side Effects and the Misguided War on Cholesterol by Duane Graveline (Author) If you are on a statin drug or are thinking of going on a statin, this fully referenced book, Statin Drug Side Effects, is a "must read" for you. The unacceptable legacy of statin drug use at today's high doses is a trail of chronic aches and pains, numbness, weakness, confusion, fatigue, shortness of breath and even heart failure in hordes of unsuspecting victims. Only by knowing this information, and in consultation with your healthcare professional, can you make an informed decision about your health care. If you are a user of Vytorin, Lipitor, Zocor, Crestor, Mevacor, Pravachol or Lescol you must read this book. Most of the statin side effects I discuss are unknown to your busy doctor. Although knowledgeable about muscle and liver problems, few have heard of statin amnesia and... |
 |
What You Must Know About Statin Drugs & Their Natural Alternatives by Jay S. Cohen (Author) |
 |
Triumph of the Heart: The Story of Statins by Jie Jack Li (Author) Over 25 million people in the U.S. alone have benefited from statins--such drugs as Lipitor, Zocor, Crestor, Pravachol, and other cholesterol-lowering medicines--in preventing stroke, heart attack, and other forms of coronary heart disease. But how did these remarkable, life-saving drugs come into being? In Triumph of the Heart, Dr. Jie Jack Li, a medicinal chemist and expert on drug discovery, tells for the first time the fascinating story of statins. Drawn from discussions with many scientists involved in the discovery and development of these drugs, the book illuminates the human side of science by revealing the role played by persistence, luck, and sudden insight that characterize major discoveries. For scientists in the drug industry, health care professionals, students of medicine,... |
 |
Aidan C-Statin - 120 Capsules by Aidan C-Statin, a naturally occurring plant extract, contains a patented proteoglycan molecule (PGM) from field bindweed that is a potent angiogenesis inhibitor. Studies have demonstrated PGM to be 100 times stronger than shark cartilage. Used and recommended by healthcare professionals around the world. C-STATIN is a proprietary extract of Convolvulus arvensis hat contains high concentrations of active PGMs. |
|
Statin the Facts by P. | |
 |
Statin Boy & Cholesterol Kid by Today's Icons Wall sculpture depicting modern day icons, cholsterol and its antidote Statin pill, ready for hanging! |
 |
Blackhawk 6" Statin Chrome Blackhawk Adjustable Wr by Blackhawk Adjustable - Wrenches Tool Type: Adjustable Wrench Overall Length: 6 Opening Size: 15/16 Finish/Coating: Matt Chrome |
 |
Natural Alternatives to Lipitor, Zocor & Other Statin Drugs: What to Use And Do to Help Lower Your Bad Cholesterol (Square One Health Guides) by Jay S. Cohen (Author) |
|
FLUSH MOUNT CEILING SUB STATIN by Aiphone |
| © 2009 BrightSurf.com |